| News
GETEC acquires Infrapark Baselland
20.11.2018
The energy services provider GETEC is acquiring Infrapark Baselland AG and its activities from the chemicals company Clariant. GETEC also intends to acquire Novartis’s facilities in the neighbouring Schweizerhalle, thus boosting the site’s attractiveness.
Clariant, Infrapark Baselland AG and GETEC recently signed the agreement for the planned sale to GETEC, announced a statement from Infrapark Baselland AG. According to the terms, the transaction will be completed by the end of the year.
GETEC is also acquiring Novartis’s production and infrastructure facilities in the Schweizerhalle site. The move signals the creation of a “new and diversified industrial park with economic significance for the entire region”, writes the statement.
“We are very pleased to have found in GETEC an owner for Infrapark Baselland AG, which has the necessary know-how to operate, integrate and develop industrial parks. I am convinced that this step will give the Schweizerhalle location and thus the employees an attractive future perspective,” commented Oliver Kinkel, head of region Europe at Clariant, in the statement.
With GETEC as operator, Schweizerhalle will gain competitiveness as a chemical life science park and create better growth opportunities “for new companies operating on the site”. A first company has already signed to move into the Schweizerhalle in the coming year: the chemicals specialist Van Baerle. Following the sale, Clariant will also remain as a tenant in Infrapark Baselland.
Share this article
Sign up to receive our newsletter in your inbox.
You might also be interested in
docdok.health involved in coronavirus research project
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.
Read More
Celonic agrees cooperation to combat coronavirus
The Basel-based biopharmaceutical company Celonic Group has agreed a partnership with Airway Therapeutics from the USA. Together, the two companies are planning to develop a drug to treat coronavirus.
Read More
Idorsia receives payment of 45 million US dollars
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..
Read More
Humard robot disinfects using UV light
Humard has developed a robot that can disinfect spaces using UV light. For this, the system manufacturer from the canton of Jura has adapted a mobile industrial robot that is otherwise used in warehouse logistics.
Read More
Roche authorized to distribute coronavirus antibody tests
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.
Read More
Basel is the most popular Swiss location for headquarters
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.
Read More
Healthtech sector growing rapidly in the Basel Area
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.
Read More
Support program has roots in Basel
The online program Selfapy supports people suffering from mental health conditions during the coronavirus lockdown. BaselArea.swiss has provided startup help by way of its DayOne initiative.
Read More
University Hospital Basel treats coronavirus patients with plasma
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.
Read More
Botnar Research Center advancing research into coronavirus
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
Read More
